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Osteoporosis, a highly heritable disease, is characterized mainly by low bone-mineral density (BMD), poor bone geometry, and/or
osteoporotic fractures (OF). Copy-number variation (CNV) has been shown to be associated with complex human diseases. The contri-
bution of CNV to osteoporosis has not been determined yet. We conducted case-control genome-wide CNV analyses, using the Affyme-
trix 500K Array Set, in 700 elderly Chinese individuals comprising 350 cases with homogeneous hip OF and 350 matched controls. We
constructed a genomic map containing 727 CNV regions in Chinese individuals. We found that CNV 4q13.2 was strongly associated
with OF (p ¼ 2.0 3 104, Bonferroni-corrected p ¼ 0.02, odds ratio ¼ 1.73). Validation experiments using PCR and electrophoresis,
as well as real-time PCR, further identiﬁed a deletion variant of UGT2B17 in CNV 4q13.2. Importantly, the association between CNV
of UGT2B17 and OF was successfully replicated in an independent Chinese sample containing 399 cases with hip OF and 400 controls.
We further examined this CNV’s relevance to major risk factors for OF (i.e., hip BMD and femoral-neck bone geometry) in both Chinese
(689 subjects) and white (1000 subjects) samples and found consistently signiﬁcant results (p ¼ 5.0 3 104 0.021). Because UGT2B17
encodes an enzyme catabolizing steroid hormones, we measured the concentrations of serum testosterone and estradiol for 236 young
Chinese males and assessed their UGT2B17 copy number. Subjects without UGT2B17 had signiﬁcantly higher concentrations of testos-
terone and estradiol. Our ﬁndings suggest the important contribution of CNV of UGT2B17 to the pathogenesis of osteoporosis.Introduction
Copy-number variation (CNV) is a common type of geno-
mic variability, with variations in the size of DNA frag-
ments ranging from 1 kilobase (Kb) to several megabases
(Mb). CNVs, which may include duplications or dele-
tions,1–3 can inﬂuence gene expression by disrupting cod-
ing sequences, perturbing long-range gene regulation, or
altering gene dosage, and these effects could contribute
to phenotypic variations or disease risk.4–6 CNVs can ac-
count for nearly 20% of the total detected genetic variation
in gene expression.7
CNVs have been shown to be associated with several dis-
tinct complex human diseases.8–11 As SNP-genotyping
technology has improved, a number of studies using ar-
ray-based methods have successfully identiﬁed CNVs re-
lated to speciﬁc complex human disorders. For example,
Friedman et al.12 found several copy-number changes asso-
ciated with mental retardation in children by using Affy-
metrix Human Mapping 100K Arrays, and Marshall
et al.11 used Affymetrix Human Mapping 500K Arrays to
detect several copy-number changes that were associated
with increased susceptibility to autism spectrum disorders
(MIM 209850).The AmericanOsteoporosis (MIM 166710) is the most common meta-
bolic bone disease, generally characterized by low bone-
mineral density (BMD), poor bone quality (characterized
by bone geometry, etc.), and/or increased susceptibility to
low-impact osteoporotic fractures (OF). Although bone ge-
ometry correlates with BMD in measurements, it might
play an important role independent of BMD indetermining
bone quality.13 Therefore, BMD and bone geometry are two
major measurable and studied risk factors used to predict
susceptibility to OF, the ultimate clinical outcome of osteo-
porosis. It is widely accepted that variation in BMD and
bone geometry, as well as risk for OF, are largely determined
by genetic factors, but the overwhelming majority of ge-
netic variation accounting for osteoporosis risk has not
been determined.14–17 Previous investigations, including
recent genome-wide association studies,18–21 have discov-
ered several genes or SNPs that appear to enhance the risk
of developing osteoporosis. Collectively, however, all of
these implicated genes or SNPs account for no more than
5% of the risk for developing osteoporosis. Consequently,
it has become important to explore the possibility that
someof the remaining undiscovered genetic factors that in-
ﬂuence risk of osteoporosis are due to genomicmechanisms
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In this study, we ﬁrst performed case-control genome-
wide CNV analyses using Affymetrix Human Mapping
500K Arrays, which are effective in identiﬁcation of geno-
mic CNVs.2,22 The study population included 700 elderly
Han Chinese subjects comprising 350 cases with a history
of hip OF and 350 healthy and matched controls. On the
basis of the mapping results for genomic CNVs, we con-
ducted association analyses to identify CNVs underlying
susceptibility to OF. For those CNVs that were signiﬁcantly
associated with OF, we performed further analysis using
PCR and electrophoresis, as well as real-time PCR, to vali-
date and ﬁne map the CNV region for speciﬁc genes in-
volved. We identiﬁed a CNV of the UGT2B17 gene (UDP
glucuronosyltransferase 2 family, polypeptide B17 [MIM
601903]) that was associated with risk of OF. More impor-
tantly, this CNV’s association with OF was successfully rep-
licated in an independent Chinese sample consisting of
399 cases with hip OF and 400 controls. We further de-
tected the signiﬁcant relevance of this CNV to hip BMD
and femoral neck (FN) bone geometry using two indepen-
dent samples of 689 unrelated Chinese subjects and 1000
unrelated white subjects. Our ﬁndings strongly support
the importance of CNV of UGT2B17 in the pathogenesis
of osteoporosis.
Subjects and Methods
Study Subjects
The study was approved by the local institutional review boards or
the ofﬁce of research administration of all participating institu-
tions. After signing an informed consent, all subjects received
assistance in completing a structured questionnaire including
questions about anthropometric variables, lifestyle, and medical
history.
Chinese Genome-Wide Analyses (GWA) Sample
This GWA sample consisted of 350 patients with a history of hip
OF and 350 healthy age-matched controls. All subjects were unre-
lated northern Han Chinese adults living in the city of Xi’an and
its neighboring areas. Affected individuals with low-impact hip
fractures were recruited from afﬁliated hospitals of Xi’an Jiaotong
University. Inclusion criteria for cases were (1) age< 80 yrs and age
at onset > 55 yrs (all women were postmenopausal), (2) minimal
trauma fracture, usually due to falls from standing height or less,
and (3) fracture site at the femoral neck or intertrochanter regions.
Hip fracture was identiﬁed through physician diagnosis according
to radiological reports or X-ray services; patients with pathological
fractures due to known disease conditions or syndromes or with
high-trauma fractures (such as those from a motor-vehicle acci-
dent) were excluded.
Healthy control subjects were enrolled by use of local advertise-
ments. They were geography- and age-matched to the cases. Inclu-
sion and exclusion criteria for controls included the stipulations
that (1) age at exammust be > 55 yrs, without any fracture history
(all female controls were postmenopausal) and that (2) subjects
with chronic diseases and conditions that might potentially affect
bone mass, structure, or metabolism were excluded. These exclu-
sions ensure that controls are less likely to suffer OF during the re-
mainder of their life, as compared with the general population.
Diseases or conditions resulting in exclusion included chronic664 The American Journal of Human Genetics 83, 663–674, Decembdisorders involving vital organs (heart, lung, liver, kidney, brain),
serious metabolic diseases (diabetes, hypo- and hyperparathyroid-
ism, hyperthyroidism, etc.), other skeletal diseases (Paget’s disease,
osteogenesis imperfecta, rheumatoid arthritis, etc.), chronic use of
drugs affecting bone metabolism (e.g., hormone-replacement
therapy, corticosteroid therapy, anticonvulsant drugs), and mal-
nutrition conditions (such as chronic diarrhea, chronic ulcerative
colitis). Also included in the inclusion and exclusion criteria was
the stipulation that (3) subjects taking anti-bone-resorptive or
bone anabolic agents or drugs, such as bisphosphonates, were
excluded.
Chinese Replication Sample
For replication of the CNV’s association with hip OF, an indepen-
dent Chinese sample containing 799 unrelated Han subjects
(399 cases with hip OF and 400 healthy age-matched controls)
was used. All of the subjects resided in the same area as the above
Chinese GWA sample, and the sample inclusion and exclusion cri-
teria for cases and controls were the same as those adopted in the
recruitment of the above GWA sample.
The signiﬁcance and relevance of the CNVs identiﬁed as signif-
icant for OF were subsequently evaluated for hip BMD and femoral
neck (FN) bone geometry variations in two independent samples
(Chinese unrelated sample and white unrelated sample); descrip-
tions are given below.
Chinese Unrelated Sample
This sample contained 689 unrelated ethnic Han subjects residing
in the same area as the above Chinese samples. Exclusion criteria
were the same as those adopted in the recruitment of the control
subjects in the above sample and have been detailed in our earlier
publication.23
White Unrelated Sample
This sample consisted of 1000 unrelated subjects, who were all
white individuals of Northern European origin living in Omaha,
NE and its surrounding regions in midwestern USA. They were de-
ﬁned by the same exclusion criteria as those used in the above Chi-
nese unrelated sample.
Chinese Young Male Sample
Because the CNV that we identiﬁed consistently signiﬁcant in the
above samples encodes an enzyme catabolizing steroid hormones,
we used a sample of young Han Chinese males to examine the re-
lationship between the CNV of interest and serum sex hormone
levels. This sample consisted of 236 unrelated, male ethnic Han
subjects from ages 22 to 28 who resided in the same area, but
were independent of, the above Chinese samples. Sample exclu-
sion criteria were the same as those adopted in the recruitment
of control subjects in the above case-control Chinese samples.
BMD and Bone-Geometry Measurements
The Chinese and white unrelated samples were measured for hip
BMD and bone-geometry parameters at the FN. The same model
of instrument and protocol were used for both samples. Hip
BMD values were measured via dual-energy X-ray absorptiometry
(DXA) with Hologic 4500 scanners (Hologic, Bedford, MA, USA)
that were calibrated daily. The coefﬁcient of variation (CV) for
hip-BMD measurements was less than 1.5% in both populations.
Using DXA-derived FN BMD and bone size, we estimated two FN
geometric variables. The algorithm was described earlier and has
been extensively used.24–26 The estimated FN geometric variables
are buckling ratio (BR), an index for bone structural instability,
and cortical thickness (CT), an important biomechanical determi-
nant of bone strength.er 12, 2008
Genome-wide Genotyping and Quality Control
Genomic DNA was extracted from peripheral-blood leukocytes
with the use of standard protocols. Affymetrix Human Mapping
500K Array Sets (Affymetrix, Santa Clara, CA, USA), which con-
sisted of two chips (Nsp and Sty) with ~250,000 SNPs each, were
used for genotyping each subject from the Chinese GWA sample
and the randomly selected white unrelated sample, according to
the Affymetrix protocol. In brief, approximately 250 ng of geno-
mic DNA was digested with restriction enzyme NspI or StyI. Di-
gested DNA was adaptor ligated and PCR ampliﬁed for each en-
zyme-digested sample. Fragment PCR products were then labeled
with biotin, denatured, and hybridized to the arrays. Arrays were
then washed and stained with Phycoerythrin on Affymetrix Fluid-
ics Station FS450 and scanned with the GeneChip Scanner 3000
7G for quantitation of ﬂuorescence intensities. Data management
and analyses were conducted with the Affymetrix GeneChip
Operating System.
Genotyping calls were determined from the ﬂuorescence inten-
sities with the use of the DM algorithm with a 0.33 p value set-
ting,27 as well as the BRLMM algorithm.28 As a result of the efforts
of repeat experiments, all of the samples had a call rate ofR 95%
and were thus included in subsequent analyses. The ﬁnal mean
BRLMM call rates reached a high level of 99.02% and 99.14% for
the Chinese (n ¼ 700) and white (n ¼ 1000) samples, respectively.
Assessment of Genetic Background
The STRUCTURE 2.2 program29 and the method of genomic con-
trol30 were applied to the Chinese GWA sample and the white un-
related sample for the detection of possible population stratiﬁca-
tion. For structure analysis, in each sample, 2000 SNPs tested to
be in Hardy-Weinberg equilibrium were randomly selected ge-
nome-wide for clustering of all of the subjects. The program uses
a Markov chain Monte Carlo (MCMC) algorithm to cluster indi-
viduals into different cryptic subpopulations on the basis of multi-
locus genotype data. Potential substructure was estimated under
an a priori assumption of K ¼ 2 discrete subpopulations. For geno-
mic control, we estimated the inﬂation factor (l) on the basis of
genome-wide SNP information.
CNV Calculation
CNV Analysis of Autosomes in the GWA Sample by CNAT
DNA CNVs were calculated with the Affymetrix GeneChip Chro-
mosome Copy Number Analysis Tool 4.0 (CNAT 4.0), which im-
plements a Hidden Markov Model (HMM)-based algorithm to
identify chromosomal gains and losses by comparing the signal
intensity of each SNP probe set for each OF sample against a refer-
ence set. As an initial analysis, we used 350 unrelated control sub-
jects as the reference set. We estimated CNVs from cases with OF
by comparing the cases to the reference set. In calculating CNVs
for controls, when an individual subject was the test sample, he
or she was excluded from the reference set, so that the reference
set contains all control subjects except the one being tested.
CNV was deﬁned when there were at least three consecutive
SNPs showing consistent deletion or duplication. Because it was
not possible to delineate the exact boundaries of each CNV with
genome-wide SNP-genotyping arrays, we used the positions of
SNPs to approximate CNV boundaries. After putative variant inter-
vals of CNVs were identiﬁed in each individual, we used the fol-
lowing criteria to determine the boundaries of CNV regions
(CNVR) (Figure S1, available online). If two individual CNVs over-
lapped, we merged them as a CNVR, using as boundaries the max-The Americanimum-interval SNPs selected from these two CNVs. When the in-
terval of the next overlapping individual CNV exceeded this
CNVR, the boundaries would extend accordingly.31 In brief,
a CNVR represented a union of overlapping CNVs. We used
CNVRs to construct the genomic CNV map in Chinese samples.
CNV Analysis of Chromosome X in the GWA Sample by CNAT
CNV of chromosome X was analyzed with CNAT with the use of
the corresponding male or female reference set as follows. Each
male case subject with OF was compared with a reference set com-
prising all 173 male controls, and each female OF case subject was
compared with a reference set comprising all 177 female controls.
In calculating CNVs of controls, when a male or female was the
test sample, he or she was excluded from the corresponding refer-
ence set, so that the reference set contained all control subjects
except the one being tested.
Analysis of Association between CNV
and OF in the GWA Sample
For association analyses, we used the following procedure to rede-
ﬁne the CNVs (those with frequencies exceeding 1%) contained in
the CNVRs. We divided complex CNVRs (illustrated in plots C–E
in Figure S1), including individual CNVs with discordant bound-
aries but overlapping regions, into several sub-CNVRs, so that
the resulting sub-CNVRs had the same conﬁgurations as those in
plots A and B in Figure S1. Thus, all CNVRs or sub-CNVRs con-
tained only one kind of CNV with the same boundaries as those
of their corresponding CNVR or sub-CNVR. CNVs with frequen-
cies > 1%, deﬁned by the above procedure, were selected for asso-
ciation analyses. For each CNV, we adopted the nonparametric
Mann-Whitney U test to evaluate the signiﬁcance of frequency-
distribution differences, between cases and controls, using SPSS
13.0 software.8,9 Two-tailed p values were estimated by 100,000
Monte Carlo simulations. p values < 0.05 in our study were con-
sidered nominally signiﬁcant and were subjected to Bonferroni
correction to account for multiple comparisons. The conservative
signiﬁcance threshold for a single test was assessed at a type _ error
rate of 0.05/N. N was the total number of the tested CNVs. For the
signiﬁcant CNVs, we used a multivariate logistic-regression model
to examine their relation to OF risk, taking into account potential
covariates such as height, weight, sex, age, and age2.
CNV-Validation Experiments
As described later, in the Results section, our initial CNAT analyses
identiﬁed a CNV at 4q13.2 that was signiﬁcantly associated with
risk of OF. Previous studies showed that this region was a recombi-
nation ‘‘hotspot’’ regionwith deletion.2,31–34 Hence, we performed
the following experiments in order to validate this CNV.
PCR and Electrophoresis Experiments
PCR and electrophoresis experiments yielded DNA fragments that
could be clearly distinguished for CNVswith andwithout homozy-
gous deletion. Thus, these methods could be used to unambigu-
ouslydetect and/or validate genotypeswith ahomozygousdeletion
at the CNV. Twenty subjects for each copy-number genotype, pre-
dicted by CNAT with the initial reference set, were selected for ex-
perimental analyses. Reactions were performed on genomic DNA
samples with a total of 20 ml reaction volume containing 10 ml 2 3
Taq PCR Master Mix (TIANGEN Biotech, Beijing, China), 10 pmol
forward and reverse primers, and 50 ng of genomic DNA. Primers
were designed with Primer Express 5.0 software from Applied
Biosystems (Forward primer 50-GGCAAAACAGAAGCACATT-30,
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incubationwas carried out at 94C for 5min, followed by 30 cycles
at 94C for 30 s, 60C for 1 min, and 72C for 3 min in an Eppen-
dorf Mastercycler (Eppendorf AG, Hamburg, Germany). All PCR
products were examined by electrophoresis on 1.5% agarose and
TBE gels and photographed with an Alpha Innotech Imager
(Alpha Innotech, San Leandro, CA, USA). We found that the locus
4q13.2, inferred to have two copy numbers by CNAT, actually
represented a homozygous deletion (see Results).
Reanalysis of CNV 4q13.2 by CNAT with New Reference Set
On the basis of the results of the PCR and electrophoresis experi-
ments, weneeded to reanalyze CNV4q13.2 usingCNAT for the fol-
lowing reasons. Estimation of raw copy numbers from SNP-map-
ping array data is based on the ratio of SNP probe-set signal
intensity for each test sample versus the average for a reference
set,which is assumed tohave a copynumberof twoat all autosomal
locations.Within a large reference set, the average copynumber for
most regions of human chromosomes is likely to be close to two.
However, when a large reference set includes dominantly frequent
polymorphisms in a region (such as deletions in this study), results
of CNAT analyses for CNVs in this region might be skewed.35 Dur-
ing PCR and electrophoresis experiments, we found a high fre-
quencyof homozygous deletions (75.4%) in the reference set. Con-
sequently, it is likely that average intensity values for the reference
setwere too low,with the result that relativelyhigh inaccuracy rates
might be obtained in inferring heterozygous deletions and homo-
zygoteswithout deletion (i.e., having two copies of theCNV), as re-
cently shown.35 Therefore,we used all subjectswith a nonhomozy-
gous deletion in the CNV at 4q13.2 and with sufﬁcient average
signal intensity for a reanalysis with CNAT as the reference set
(n ¼ 216) to recall CNV genotypes in this region. The newly ascer-
tained genotypes at the CNVwere used in all subsequent analyses.
Real-Time PCR
According to the results of the above section, ‘‘Reanalysis of CNV
4q13.2 by CNAT with the New Reference Set,’’ we selected 20 sub-
jectspredicted tohavehomozygousdeletions, 20 subjectspredicted
to have heterozygous deletions, and all of the subjects (n¼ 16) pre-
dicted to be diploid to perform real-time PCR, in order to assess the
statistical signiﬁcance of differences inDNA-ampliﬁcation rates be-
tween groups with different copy numbers. The ampliﬁcation rate
is highly correlatedwith the copynumbers at theCNV. Theprimers
were the same as those described above. Reactions were conducted
in a 384 plate with the ABI 7900HT Sequence Detector system (Ap-
plied Biosystems, Foster City, CA, USA). Amplicons were designed
against the putative altered locus and a control locus (Actin), which
was used for controlling differences in genomic-DNA purity and
concentrationofdifferent samples. PCRwasperformed in a20ml re-
actionvolumecontaining10ml Power SYBR-GreenPCRMasterMix
(Applied Biosystems), 10 pmol forward and reverse primers, and
50 ng of genomic DNA. The reaction cycling conditions were
95C for 10 min, followed by 40 cycles at 95C for 15 s and at
60C for 1min. SequenceDetection Software (SDS)was used for ex-
porting the threshold cycle (Ct) data and further analyzing differ-
ences in Ct values (DCt) between the test locus and the control
locus. For groups predicted to have different copy numbers by
CNAT analyses, a t test, with the signiﬁcant threshold deﬁned by
p < 0.05, was used for comparing DCt values to determine the sta-
tistical signiﬁcance of these predicted copy-number differences.
Fine Mapping for CNV 4q13.2
With the Affymetrix Human Mapping 500K Array, CNV 4q13.2
contained three SNPs, namely rs4260611 (position: 69,067,201),666 The American Journal of Human Genetics 83, 663–674, Decembrs4492065 (position: 69,072,839), and rs4860308 (position:
69,172,267). According to the UCSC Human Genome Browser,
the UGT2B17 gene is located within this region. As a result of
a lack of direct DNA-sequence data, the positions of rs4260611
and rs4860308 were not the exact boundaries of CNV 4q13.2.
Consequently, for the purpose of ﬁne mapping and identiﬁcation
of the susceptible gene(s) inside the CNV, we extended the CNV
boundaries to the neighboring SNPs, i.e., rs1730872 (next to
rs4260611) and rs293430 (next to rs4860308), to be inclusive.
The interval between these two SNPs is the maximal region that
will cover this CNV (physical position: 68,871,643–69,625,838).
Four additional protein-coding genes, named YTH domain
containing 1 (YTHDC1); transmembrane protease, serine 11E
(TMPRSS11E [MIM 610399]); transmembrane protease, serine
11E2 (TMPRSS11E2); and UDP glucuronosyltransferase 2 family
and polypeptide B15 (UGT2B15 [MIM 600069]), are localized
within this region (Figure 2BII). In order to determine whether
these genes were involved in this CNV, we used the same geno-
mic-DNA samples as those described in the ‘‘Real-Time PCR’’ sec-
tion in the SupplementalMaterial andMethods section of the Sup-
plemental Data to conduct separate real-time PCR experiments for
the estimation of copy numbers for the above ﬁve genes (primer
sequences are presented in Table S1). Because a high level of se-
quence identity exists between UGT2B17 and UGT2B15, we used
gene-speciﬁc markers described by Wilson et al.34 to distinguish
UGT2B17 and UGT2B15 (marker C: within exon 1 of UGT2B17;
marker G: within exon 1 of UGT2B15).
Subsequently, in order to further validate UGT2B17 gene dele-
tion, we selected three additional markers described by Wilson
et al,34 which were marker D, located in the 50 upstream region
of UGT2B17; marker E, located within exon 6 of UGT2B17; and
a deletion marker, J, for UGT2B17 (see Figure S2) for performance
of PCR ampliﬁcation (PCR procedure described in the Supplemen-
talMaterial andMethods section of the Supplemental Data) on the
same subjects used in the above real-time PCR experiments. The
ability to amplify markers D and E indicated the presence of
UGT2B17. The ability to amplify marker J indicated the absence
of the genomic region covering UGT2B17.
Replication of CNV’s Association with OF
To validate the association between the CNV of UGT2B17 and OF,
we genotyped the UGT2B17 gene copy number, by real time PCR,
using UGT2B17 gene-speciﬁc marker C, in the Chinese replication
sample. The reaction conditions were the same as those described
in the above ‘‘Real-Time PCR’’ section. Then, we used marker J to
perform PCR and electrophoresis experiments in order to validate
and differentiate subjects with one or two copy numbers. Associa-
tion analysis was conducted via the same procedure as that de-
scribed in the above ‘‘Analysis of Association between CNV and
OF in the GWA Sample’’ section. Because this test was for hypoth-
esis-based conﬁrmation, a one-sided p value< 0.05 was considered
signiﬁcant.
Association Analyses between CNV and BMD or Bone
Geometry in Chinese Unrelated Sample
To further explore the relationship between UGT2B17 gene copy
number and osteoporosis risk, we performed association analyses
between this CNV and BMD or bone geometry in the Chinese
unrelated sample. The UGT2B17 gene copy number was geno-
typed via the same procedure as that described in the above
‘‘Replication of CNV’s AssociationwithOF’’ section. The signiﬁcanter 12, 2008
(p < 0.05) terms of height, weight, sex, age, age2, and time since
menopause (for postmenopausal females) were used as covariates
in multiple-regression analyses for the adjustment of derived
BMD, BR, and CT values. Association analyses were performed
for the adjusted residues by ANOVA in Minitab software (Minitab,
State College, PA, USA). A one-sided p value < 0.05 was considered
signiﬁcant.
Population Differentiation of CNV
Previous studies suggested that some CNVs might have elevated
population differentiation.2,6 In order to test potential ethnic dif-
ferentiation and associated effects of the CNVs that were signiﬁ-
cantly associated with osteoporosis in Chinese subjects, we calcu-
lated copy numbers for these CNVs with CNAT in the 1000 white
subjects, using genotype data from the Affymetrix Human Map-
ping 500K Array.36 Three hundred out of the successfully geno-
typed 1000 white subjects were randomly selected as an initial
reference set, and all 1000 subjects were screened by CNAT with
the use of this reference set. When a subject in the reference set
was screened by CNAT for CNV, however, he or she was excluded
from the reference set. Using the protocol for CNAT-based CNV
analyses that we used in the Chinese GWA sample, we consistently
performed reanalysis by using an updated reference set including
230 subjects with two copy numbers. We subsequently performed
association analyses between the CNVs and BMD and/or bone ge-
ometry parameters (all tested and adjusted for covariates of height,
weight, sex, age, age2, and time since menopause [for postmeno-
pausal females only] by multiple regression) in white individuals
by ANOVA to examine whether they had consistent effects on
risk for osteoporosis. The signiﬁcance level was deﬁned as a one-
sided p value < 0.05.
Relationships between Serum Sex Hormones
and UGT2B17 Gene Copy Number
The UGT2B17 gene encodes a key enzyme responsible for glucur-
onidation of androgens and their metabolites in humans. Andro-
gen is a major source for estrogen, and both have direct effects in
stimulating bone formation. Therefore, it is reasonable to hypoth-
esize that UGT2B17 inﬂuences serum androgen or estrogen con-
centrations, speciﬁcally through gene-dosage changes via CNVs.
To assess this hypothesis, we examined the relationship between
serum total testosterone or estradiol levels and UGT2B17 gene
copy number, respectively. Two hundred and thirty six unrelated
Chinese young male subjects aged 22–28 yr (mean 23.6 5 1.8)
were recruited. After the subjects fasted overnight, 4 ml blood
samples were collected from them at roughly 9 a.m. Serums were
prepared from clotted blood and stored at 80C until use. Serum
testosterone and estradiol concentrations were quantiﬁed by Io-
dine [125I] Testosterone Radioimmunoassays (RIA) Kit (Tianjing
Nine Tripods Medical & Bioengineering, China; limit of detection
2.1 pg/ml, intra-assay CV 7%, inter-assay CV 8%) and Iodine [125I]
Estradiol RIA kit (Tianjing Nine TripodsMedical & Bioengineering,
China; limit of detection 2.1 pg/ml, intra-assay CV 7%, inter-assay
CV 9%), respectively. All experimental procedures were conducted
according to the manufacturer’s instructions.
UGT2B17 gene copy number was genotyped by the same proce-
dure as described in the section entitled ‘‘Replication of CNV’s
Association with OF.’’ Differences in serum sex-steroid levels be-
tween the different genotypes (UGT2B17 homozygous deletion
versus one or two copy numbers) were compared in Minitab soft-
ware with a Student’s t test.The AmericanResults
The basic characteristics of all sample sets are summarized
in Table 1. In testing for potential within-population strat-
iﬁcation of our Chinese GWA sample and randomly se-
lected white unrelated sample, the STRUCTURE program
showed that all subjects within each population were clus-
tered together as one homogeneous sample. The estimated
l values were 1.02 and 1.01 for our Chinese GWA sample
and white unrelated sample, respectively. These results in-
dicate that there is no detectable signiﬁcant population
stratiﬁcation within our Chinese and white samples.
Genome-wide CNV Distribution in the Chinese GWA
Sample
Excellent SNP call rates were obtained for DNA samples
with the use of the 500K SNP mapping array. The ﬁnal av-
erage genotyping call rate of the entire sample is 99.02%,
which demonstrates high-quality allele-intensity data in
this study. We used CNVRs to construct the genomic
CNV map. By combining all of the individual CNV data
analyzed by CNAT in the Chinese sample, we assembled
a genomic map consisting of 727 CNVRs (Table S2) with
an average and median size of 349.4 Kb and 223.6 Kb, re-
spectively, covering 8.5% (254 Mb) of the human genome.
Figure 1 shows the genomic distribution of these 727
CNVRs, of which 439 were singletons (marked by green
lines) and 74 had CNVs with frequencies exceeding 1%
(marked by red lines).
Association Analyses of Common CNVs
in the Chinese GWA Sample
In order to detect the distribution difference between cases
and controls, we redeﬁned 116 common CNVs (Figure S1)
with >1% frequency from these 74 CNVRs for perfor-
mance of the Mann-Whitney U test. We observed that
CNV 4q13.2 had a signiﬁcant distribution difference. Ac-
cording to the initial CNAT analyses, CNV 4q13.2 had
three genotypes (Figure 2AI), namely, individuals with
four, three, and two copy numbers. Results of PCR and
electrophoresis experiments, however, showed that the
CNV locus at 4q13.2 inferred to have two copy numbers
by CNAT analyses with the initial reference data set, actu-
ally represented a homozygous deletion (Figure 2AII).
Thus, we reanalyzed CNV 4q13.2 in the total sample
with CNAT (See the Subjects and Methods section for de-
tails), and we concluded that there were 484 subjects
(69.1%) with a homozygous deletion (Figure 2BIc), 200
subjects (28.6%) with a heterozygous deletion (Figure 2-
BIb), and 16 subjects (2.3%) with two copy numbers
(Figure 2BIa). The newly ascertained genotypes at CNV
4q13.2 were then used in all subsequent analyses. Real-
time PCR analyses further conﬁrmed that the average
DCt value for DNA samples with two copy numbers was
signiﬁcantly lower than that obtained from DNA with
a heterozygous deletion at 4q13.2 (p ¼ 2.8 3 105). ThisJournal of Human Genetics 83, 663–674, December 12, 2008 667
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.668 The American Journal of Human Genetics 83, 663–674, Decemresult supports the conclusion that the DNA copy number
from samples inferred by CNAT as having two copies was
indeed greater than the DNA copy number from samples
inferred by CNAT as having one copy. DNA samples
with homozygous deletion were observed as nonspeciﬁc
ampliﬁcation with weak signal intensity or failed ampliﬁ-
cation.
Table 2 lists the distribution of CNV 4q13.2 in the GWA
sample. The prevalence of the deletion polymorphism in
controls was concordant with that expected from the
Hardy-Weinberg equilibrium (HWE) test (p ¼ 0.63). The
p value for the distribution difference between cases and
controls was calculated to be 2.0 3 104 [95% conﬁdence
interval (CI): 0–4.83 104] on the basis of CNATreanalyses
with the updated reference set. This p value remained sig-
niﬁcant even after conservative Bonferroni correction for
multiple testing by the number (n ¼ 116) of CNVs exam-
ined (corrected p¼0.023).Whenall covariateswere consid-
ered simultaneously, multivariate logistic-regression analy-
sis indicated that the odds ratio (OR) was 1.73 (95% CI:
1.22–2.45, subjects with a heterozygous deletion and
two copynumbers versus subjects with a homozygous dele-
tion, p ¼ 0.001). This result suggests that CNV in 4q13.2
was a signiﬁcant predictor for the risk of hip OF, indepen-
dent of the adjusted covariates (i.e., age, sex, height, and
weight).
Fine Mapping for CNV 4q13.2
Five protein-coding genes, including UGT2B17,
YTHDC1, TMPRSS11E, TMPRSS11E2, and UGT2B15, are
located within CNV 4q13.2 and its ﬂanking region
(Figure 2BII). In order to determine whether these genes
were involved in this CNV, we conducted independent
real-time PCR experiments to estimate copy numbers
for each of these ﬁve genes. Gene copy-number
deletion was only observed for UGT2B17 (Table S1), indi-
cating that UGT2B17 is the only gene contained in CNV
4q13.2.
In order to further validate UGT2B17 gene deletion, we
selected three additional markers (marker D: within 50 up-
stream region of UGT2B17, marker E: within exon 6 of
UGT2B17, marker J: a deletion marker for UGT2B17) for
the performance of PCR and electrophoresis analysis
(Figure S2). The results of these experiments showed that
the ability to amplify markers D and E was concordant
with the ampliﬁcation of marker C (within exon 1 of
UGT2B17). Thus, subjects with two copies of UGT2B17
had the ability to amplify markers C, D, and E but not
marker J (Figure 2BIIIa), whereas subjects with a heterozy-
gous deletion showed the ability to amplify markers C, D,
E, and J simultaneously (Figure 2BIIIb). Subjects with a
homozygous deletion had the ability to amplify only
marker J and not C, D, or E (Figure 2BIIIc). These results
indicate that there was a deletion polymorphism in the
150 kb interval spanning the whole UGT2B17 gene
(Figure S2).ber 12, 2008
Replication of UGT2B17 Gene Copy-Number
Association with OF
In the Chinese replication sample, we detected 582 sub-
jects (72.84%) with a homozygous deletion, 209 (26.16%)
with a heterozygous deletion, and eight (1.0%) with two
copy numbers (HWE test in control: p¼ 0.19; Table 2). Sig-
niﬁcant association was successfully replicated between
UGT2B17 gene copy number and OF (p ¼ 6.34 3 103).
A logistic-regression model consistently indicated an in-
creased risk of OF in subjects with an existing UGT2B17
gene (OR ¼ 1.58, 95% C.I.: 1.12–2.22, p ¼ 0.01).
Association Analyses of UGT2B17 Gene Copy Number
in the Chinese Unrelated Sample
To further explore the relationship between UGT2B17
CNV and osteoporosis risk, we genotyped UGT2B17 gene
copy number in the Chinese sample of 689 unrelated sub-
jects, and we found 529 subjects (76.8%) with a homozy-
gous deletion, 149 (21.6%) with a heterozygous deletion,
and 11 (1.6%) with two copy numbers (HWE test: p ¼
0.92). Because the low frequency of two copy numbers of
the UGT2B17 gene was detected, we combined the subjects
with two copy numbers and those with heterozygous dele-
tion as one group for the performance of subsequent asso-
ciation analysis. Figure 3 lists the association results
between BMD, FN bone geometry (CT and BR), and the
CNV of UGT2B17. Compared to subjects with a homozy-
gous deletion, subjects with one or two UGT2B17 gene
copy numbers had signiﬁcantly lower BMD (3.4% lower,
0.855 g/cm2 versus 0.885 g/cm2, p ¼ 5.0 3 104), thinner
Figure 1. Genomic Distribution of 727
CNVRs Identified in Chinese Subjects
The approximate locations of all CNVRs are
shown by lines. CNVRs observed in only one
subject (singleton) are indicated in green,
and CNVRs identified in multiple individ-
uals are indicated in blue (<1% frequency)
and red (>1% frequency).
CT (3.5% lower, 0.138 cm versus
0.143 cm, p ¼ 0.003), and a higher
BR (5.5% higher, 12.8 versus 12.1,
p ¼ 5.0 3 104). The contribution of
the CNV of UGT2B17 to variations
in BMD, CT, and BR was 1.43%,
1.08%, and 1.46%, respectively.
Association Analyses of UGT2B17
Gene Copy Number in the White
Unrelated Sample
In the white sample of 1000 unre-
lated subjects, we detected 119 sub-
jects (11.9%) with a homozygous de-
letion, 444 subjects (44.4%) with
a heterozygous deletion, and 437 sub-
jects (43.7%) with two copy numbers (HWE test: p¼ 0.70).
We tested for the independence between genotype and
ethnic background and found that CNV of UGT2B17 had
a different frequency distribution in Chinese subjects (un-
related sample: 76.8% had homozygous deletions, 21.6%
had heterozygous deletions, and 1.6% had two copy num-
bers) than in white subjects (2 df, p < 0.0001). Consistent
with the results obtained in the unrelated Chinese sample,
higher UGT2B17 copy numbers in the white sample were
signiﬁcantly associated with lower BMD (copy numbers
0 versus 1 versus 2: 0.986 g/cm2 versus 0.973 g/cm2 versus
0.964 g/cm2, respectively; p ¼ 0.021), thinner CT (0.159
cm versus 0.156 cm versus 0.152 cm; p ¼ 0.017), and
higher BR (11.71 versus 12.01 versus 12.20; p ¼ 0.012)
(Figure 3B). In the white sample, the contribution of the
CNV of UGT2B17 to variations in BMD, CT, and BR was
0.67%, 0.71%, and 0.77%, respectively. Compared to those
with a homozygous deletion, subjects in whom the
UGT2B17 gene was present (including those with two
and one copy numbers) had a 1.77% lower BMD,
a 3.14% lower CT, and a 3.37% higher BR.
Relationships between Serum Sex Hormones
and UGT2B17 Gene Copy Number
In the 236 unrelated Chinese young males studied, we
detected 181 subjects (76.7%) with a homozygous dele-
tion, 49 subjects (20.8%) with a heterozygous deletion,
and six subjects (2.5%) with two copy numbers (HWE
test: p ¼ 0.27). Compared with those with one or two
UGT2B17 gene copy numbers, subjects with homozygousThe American Journal of Human Genetics 83, 663–674, December 12, 2008 669
Figure 2. Examples of Copy-Number Determination at 4q13.2 by CNAT Analyses with Affymetrix Human Mapping 500K Array
Data and Electrophoresis Analyses
A: CNV 4q13.2 calculated by CNAT analyses with the 350 unrelated control subjects used as the reference set.
AI: Three genotypes of the CNV 4q13.2: four copy numbers (a), three copy numbers (b), and two copy numbers (c). The x axis denotes
genomic position. The y axis denotes the log2 ratio, which was calculated by comparison of the allele-intensity values of the test sample
with those of the reference set.
AII: Electrophoresis analysis for PCR products (with deletion-specific primers) from the three genotypes at the CNV. Results for 4q13.2
inferred to have two copy numbers by CNAT analyses reveal no PCR products, indicating that this sample actually reflects a homozygous
deletion.
B: CNV 4q13.2 calculated by CNAT with all of the subjects with nonhomozygous deletion used as the updated reference set.
BI: Three genotypes of CNV 4q13.2: two copy numbers (a), one copy number, (b) and zero copy numbers (c).
BII: On the basis of the UCSC Human Genome Brower, five genes are located in 4q13.2. The heavy arrow above ‘‘UGT2B17’’ means that the
gene was found in CNV 4q13.2 with SNPs of rs4260611 and rs4860308 used as boundaries. When the boundaries were extended to SNPs of
rs1730872 and rs293430 (the interval between these two SNPs was the maximal potential region for this CNV), four more protein-coding
genes, named YTHDC1, TMPRSS11E, TMPRSS11E2, and UGT2B15, were found to be localized within this region (light arrows). CNV was only
observed in UGT2B17.
BIII: Electrophoresis analysis for PCR products from gene-specific markers C (within exon 1 of UGT2B17), D (within 50 upstream of
UGT2B17), and E (within exon 6 of UGT2B17) and from deletion marker J of UGT2B17 . Subjects with two copy numbers of UGT2B17
had the ability to amplify markers C, D, and E but not marker J (a). Subjects with heterozygous deletion showed the ability to amplify
markers C, D, E, and J simultaneously (b). Subjects with homozygous deletion had the ability to amplify only marker J (c). The results
revealed that there was a deletion polymorphism in a 150 kb interval spanning the whole UGT2B17 gene.670 The American Journal of Human Genetics 83, 663–674, December 12, 2008
Table 2. Distribution of UGT2B17 Copy Number or CNV 4q13.2 in Two Chinese Case-Control Samples
Sample Status
Copy Numbers
HWE p Value (95% CI) OR (95% CI)0 1 2
GWA sample case 220 119 11 – 2.0 3 104 1.73 (1.22–2.45)
control 264 81 5 0.63 (0  4.8 3 104)
Replication sample case 275 119 5 – 6.3 3 103 1.58 (1.12–2.22)
control 307 90 3 0.19 (5.9 3 103  6.8 3 103)
Fine-mapping result indicated that UGT2B17 is the only gene contained in CNV 4q13.2. Abbreviations are as follows: GWA, genome-wide analysis; HWE,
Hardy-Weinberg equilibrium; C.I., confidence interval; OR, odds ratio. p values were calculated via a nonparametric Mann-Whitney U test. Odds ratios were
calculated with a logistic-regression model (copy number 0 versus copy numbers 1 and 2), with potential covariates such as height, weight, sex, age, and
age2 taken into account.deletions of UGT2B17 had signiﬁcantly higher concentra-
tion levels of testosterone (p ¼ 0.005) and estradiol
(p ¼ 0.01) (Table 3).
Discussion
In this study, we generated a preliminary genome-wide
map of CNVRs identiﬁed in Chinese subjects and found
that nearly 80% of these CNVRs overlapped with previ-
ously reported CNVRs, according to the Database of Geno-
mic Variants. Importantly, we discovered that CNV 4q13.2
was signiﬁcantly associated with the risk of OF. This CNV
was one of the CNVs that overlapped with those reported
in previous studies, and it was located within a recombina-
tion ‘‘hotspot’’ region.2,31,32,37 CNV 4q13.2 was common
in our Chinese study samples; a high frequency of 76.8%
was found in the Chinese unrelated subjects, and this fre-
quency is consistent with the ﬁndings that Terakura et al.
observed in an East Asian sample.33 Conﬁrmatory real
time PCR experiments and replication study lent further
support for the concept that the existence of the
UGT2B17 gene in CNV 4q13.2 might increase OF risk com-
pared to a homozygous deletion in this CNV. Speciﬁcally,
in both Chinese and white samples, the presence of the
UGT2B17 gene was signiﬁcantly associated with lower
BMD, thinner CT, and higher BR, all of which have been
consistently identiﬁed asmajor risk factors for the develop-
ment of OF. Our results consistently supported the impor-
tant effect of the CNV of UGT2B17 to the pathogenesis of
osteoporosis.
CNVs might be the consequence of recurrent events via
nonallelic homologous recombination, mediated by
higher-order genomic structural features.38 Copy-number-
deletion variants can be subjected to increased selection
pressures.38 Our results revealed that CNV of UGT2B17
had an ethnic differentiation, which lends strong support
to previous ﬁndings.2,6 Copy-number deletion of UGT2B17
is much more common in Chinese subjects than in white
subjects, and the differential frequency of this deletion in
these twopopulationsmight contribute to the overall lower
risk of OF in Chinese individuals than in white individuals.
Despite this differential frequency of deletion, the relation-The Americanship betweenCNVofUGT2B17 and the risk of osteoporosis
exhibited the same trend within both Chinese and white
populations; i.e., higher gene copy numbers were associ-
ated with lower BMD, thinner CT, higher BR, and an in-
creased risk of OF in both populations.
One possible mechanism by which CNVs cause pheno-
typic diversity is by alteration of the expression of copy-
number-variant genes; i.e., dosage effects might underlie
Figure 3. Comparisons of Hip BMD, CT, and BR Values for CNVs
of UGT2B17 in Chinese and White Unrelated Samples
(A) Chinese unrelated sample.
(B) White unrelated sample.
p values were estimated with the use of an ANOVA. For the Chinese
unrelated sample, because a low frequency (1.6%) of two copy
numbers of the UGT2B17 gene were detected, we combined the
subjects with two copy numbers and heterozygous deletions as
one group to perform the association analysis. Error bars denote
standard error. Abbreviations are as follows: BMD, bone mineral
density; CT, cortical thickness; BR, buckling ratio.Journal of Human Genetics 83, 663–674, December 12, 2008 671
the biological effects of certain CNVs. The UGT2B17 gene
in CNV 4q13.2 encodes a protein belonging to the family
of uridine diphospho (UDP)-glucuronosyltransferases en-
zymes, which play a key role in the homeostasis and me-
tabolism of a number of endogenous molecules, including
steroid hormones.39,40 Chouinard et al.41 determined that
UGT2B17 encodes a critical enzyme involved in the local
inactivation of androgens; i.e., enhanced expression of
UGT2B17 inhibits the androgen-signaling pathway. Our
serum-sex-hormones analysis supported this conclusion
by showing that subjects with homozygous deletions of
UGT2B17 had signiﬁcantly higher concentrations of total
testosterone and estradiol than did subjects with one or
two copies of this gene. Additionally, it has been well es-
tablished that the steroid hormones, androgen and estro-
gen, have important roles in maintaining cancellous
bone mass and integrity.42 Androgen is a major source
for estrogen and has a direct effect in stimulating bone for-
mation. Consequently, enhanced expression of UGT2B17,
via its effects on androgen, might increase the risk of oste-
oporosis by impairing bone formation during growth and/
or favoring bone resorption over bone formation. This pro-
posed physiological mechanism is consistent with our cur-
rent ﬁndings that increasing dosage of UGT2B17 incurred
higher risk for OF, lower BMD, and poorer bone geometry.
It is notable that all the subjects in our Chinese sample
were of the same Han ethnicity and from the same geo-
graphic area and that all of the case subjects experienced
the same type of low-impact osteoporotic hip fractures.
The homogeneity of our sample minimized or eliminated
spurious CNVs and associations due to phenotypic hetero-
geneity and variation, copy-number polymorphisms in
ethnically diverse populations, or other factors caused by
population stratiﬁcation.
It is important to recognize that estimation of raw copy
numbers from SNP-mapping array data is based on the ra-
tio of SNP probe-set signal intensity for each test sample
versus a reference set. Thus, statistical software uses the av-
erage of the reference set to infer changes in copy number
by relative duplication or deletion. A larger sample size for
the reference set can improve the accuracy of copy-number
computation.35 Similarly, for a speciﬁc CNV, exclusion of
subjects with homozygous deletions from the reference
set can also improve the precision of copy-number infer-
ence, as a result, in part, of higher average signal intensities
of the reference set. Of course, the results from these statis-
tical inferences need to be validated by actual experimen-
Table 3. Relationships between Serum Testosterone
or Estradiol and UGT2B17 Copy Number
UGT2B17 Copy Numbers
p Value0 (181 subjects) 1 or 2 (49 subjects)
Testosterone (mg/l) 8.75 (2.93) 7.62 (2.45) 0.005
Estradiol (ng/l) 52.1 (17.0) 46.4 (12.0) 0.01
Data are shown as mean (standard deviation).672 The American Journal of Human Genetics 83, 663–674, Decembtation, as conducted in the current study with several
methodological approaches (PCR and electrophoresis, as
well as real-time PCR). Finally, due to concerns about the
limitations of association analyses, we did not perform as-
sociation analyses between OF and rare CNVs (i.e., CNVs
with apparent frequencies <1%) in the current study,
given that the results, even if signiﬁcant, might still occur
by chance, i.e., by sampling error.43
In conclusion, our study revealed 727 CNVs in a Chinese
Han population, though this result warrants continual re-
ﬁnement in the same population and ethnicity. We addi-
tionally determined that higher UGT2B17 gene copy num-
ber was associated with lower BMD, thinner CT, higher BR,
and increased risk of OF at the hip in both Chinese and
white populations. However, focused molecular functional
studies will be needed for conﬁrmation and clariﬁcation of
this potential mechanism. Although a genetic basis for os-
teoporosis has been well established, previous investiga-
tions have focused on the association between classical ge-
notypes (such as SNPs) and osteoporosis. To the best of our
knowledge, this is the ﬁrst study implicating gene-dosage
changes as a risk factor for osteoporosis.
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